SOURCE:

Nasdaq Stock Reports on: Uranium Resources, Inc. (NASDAQ: URRE), Jamba, Inc. (NASDAQ:JMBA), Geron Corporation (Nasdaq: GERN), Athersys, Inc. (Nasdaq:ATHX)

Hot Nasdaq Stock Reports on: Uranium Resources, Inc. (NASDAQ: URRE), Jamba, Inc. (NASDAQ:JMBA), Geron Corporation (Nasdaq: GERN), Athersys, Inc. (Nasdaq:ATHX)

http://www.Firstpennypicks.com  FPP is a 100% uncompensated micro-cap stock newsletter designed for traders. FPP Gives traders an edge in the market by alerting their members to the hottest penny stocks ready for a breakout. FPP specializes in reverse mergers, pre-promotion, and FDA approval stocks from the OTC, pink sheets, Amex, and Nasdaq markets.

 

 

Uranium Resources, Inc. (NASDAQ: URRE), Uranium Resources Inc. explores for, develops and mines uranium. Since its incorporation in 1977, URI has produced over 8 million pounds of uranium by in-situ recovery (ISR) methods in the state of Texas. URI has over 206,600 acres of uranium mineral holdings and 152.9 million pounds of in-place mineralized uranium material in New Mexico and an NRC license to produce up to 1 million pounds of uranium per year. URI has an additional 1.3 million pounds of in-place mineralized uranium material in Texas and South Dakota. (Get Full Report) http://www.firstpennypicks.com/get-your-free-research-report/

 

 

 

Jamba, Inc. (NASDAQ:JMBA), Jamba, Inc., (the "Company") owns and franchises Jamba Juice stores through its wholly-owned subsidiary, Jamba Juice Company. Jamba Juice Company is a leading restaurant retailer of better-for-you, specialty beverage and food offerings, which include great tasting, whole fruit smoothies, fresh squeezed juices and juice blends, hot coffee and teas, hot oatmeal, breakfast wraps, sandwiches and mini-wraps, California Flatbreads(TM), frozen yogurt, and a variety of baked goods and snacks. As of October 2, 2012, there were 788 store locations globally.  (Get full Analysis) http://www.firstpennypicks.com/get-your-free-research-report/

 

 

 

 Geron Corporation (Nasdaq: GERN Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, GRN1005 and imetelstat. GRN1005 is a peptide-drug conjugate that is designed to transport a proven anti-cancer drug, paclitaxel, across the blood-brain barrier by targeting low-density lipoprotein receptor-related proteins (LRPs), specifically LRP-1. GRN1005 is being evaluated in two Phase 2 clinical trials: brain metastases arising from breast cancer and brain metastases arising from non-small cell lung cancer. Imetelstat is a telomerase inhibitor that is being evaluated in three ongoing Phase 2 clinical trials: advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma.) (Get full Analysis) http://www.firstpennypicks.com/get-your-free-research-report/

 

 

Athersys, Inc. (Nasdaq: ATHX), Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem(R) cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. (Get full Analysis) http://www.firstpennypicks.com/get-your-free-research-report/

 

 

 

 

For updates and our weekly feature alerts subscribe free at:  http://www.Firstpennypicks.com

 

 

FIRST PENNY PICKS DISCLAIMER 


Please note that FirstPennyPicks.COM employees are not registered as an Investment Adviser in any jurisdiction whatsoever. This advertisement is for informational purposes only and is not intended to be a recommendation to buy or sell securities in any of the profiled companies listed here.

We do not accept compensation for any of the companies profiled in our newsletter.  We do however, from time to time buy shares in the companies profiled. If Firstpennypicks.com employees, owners, or affiliates own shares in a profiled company the amount of shares will be listed at the bottom of each email.
READ OUR FULL DISCLAIMER AT http://www.firstpennypicks.com/disclaimer/

 

 

 

 

 

Source: Elite Traders Group, LLC

Add Comment

Views by Registered Users: 0
Views by Non-Registered Users: 14
Total Like Count: 0
Total Dislike Count: 0
No Comment History